IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 Registrational OptimUM-02 trial of the darovasertib...
PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., July 31, 2026 SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA...
PR Newswire
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor...
PR Newswire
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs PR Newswire SOUTH SAN FRANCISCO, Calif., July 17, 2026 SOUTH SAN FRANCISCO, Calif., July 17, 2026...
PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., June 26, 2026 SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ --IDEAYA...
PR Newswire
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a...
PR Newswire
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SOUTH SAN FRANCISCO, Calif., June 10, 2026...
PR Newswire
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak earnings. Other stocks also down in pre-market.read more...
Benzinga
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif., June 8, 2026 SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA...
PR Newswire
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif., June 8, 2026 SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences...
PR Newswire